blood cancer Archives - Pharmaphorum

FDA puts hold on AZ and Celgene immunotherapy trials

September 8, 2017

Regulator is exploring safety of immunotherapy combinations in blood cancer

FDA puts hold on AZ and Celgene immunotherapy trials

https://pharmaphorum.com/news/fda-puts-hold-az-celgene-immunotherapy-trials/

FDA halts recruitment to three BMS Opdivo trials

September 7, 2017

FDA is investigating safety of immunotherapies in blood cancer.

FDA halts recruitment to three BMS Opdivo trials

https://pharmaphorum.com/news/fda-halts-recruitment-three-bms-opdivo-trials/

Janssen art campaign raises awareness about blood cancer

September 5, 2017

Janssen has launched a campaign to raise awareness about blood cancer, unveiling a giant art installation in London’s Paternoster

Janssen art campaign raises awareness about blood cancer

https://pharmaphorum.com/news/janssen-art-campaign-raises-awareness-blood-cancer/

Cellectis CAR-T trials on hold after patient death

September 5, 2017

Cellectis’ ‘off the shelf’ CAR-T cancer therapy has hit a major setback after the first patient treated in

Cellectis CAR-T trials on hold after patient death

https://pharmaphorum.com/news/cellectis-car-t-trials-hold-patient-death/

FDA reapproves Pfizer’s Mylotarg leukaemia drug

September 4, 2017

FDA gives green light after 7-year absence

FDA reapproves Pfizer’s Mylotarg leukaemia drug

https://pharmaphorum.com/news/fda-reapproves-pfizers-mylotarg-leukaemia-drug/

Oxford BioMedica could get $100m following CAR-T approval

September 1, 2017

UK biotech will supply key component of Novartis’ newly approved cancer cell therapy

Oxford BioMedica could get $100m following CAR-T approval

https://pharmaphorum.com/news/oxford-biomedica-get-100-following-car-t-approval/

FDA probes blood cancer immunotherapy safety

September 1, 2017

Regulator reviewing combination therapy safety after issue with Keytruda

FDA probes blood cancer immunotherapy safety

https://pharmaphorum.com/news/fda-looks-cancer-immunotherapy-blood-cancer-safety/

Adcetris cleared by NICE in aggressive blood cancer

August 31, 2017

Adcetris cleared by NICE in aggressive blood cancer

https://pharmaphorum.com/news/takedas-adcetris-cleared-nhs-funding-aggressive-blood-cancer/

Pfizer objects to NICE methods in leukaemia drug rejection

August 21, 2017

NICE has caused controversy by rejecting Pfizer’s Besponsa – a blood cancer drug that can give patients the

Pfizer objects to NICE methods in leukaemia drug rejection

https://pharmaphorum.com/news/pfizer-questions-nice-methods-besponsa/

Trending

blood cancer

FDA puts hold on AZ and Celgene immunotherapy trials

FDA halts recruitment to three BMS Opdivo trials

Janssen art campaign raises awareness about blood cancer

Cellectis CAR-T trials on hold after patient death

FDA reapproves Pfizer’s Mylotarg leukaemia drug

Oxford BioMedica could get $100m following CAR-T approval

FDA probes blood cancer immunotherapy safety

Adcetris cleared by NICE in aggressive blood cancer

Pfizer objects to NICE methods in leukaemia drug rejection

CDD for Biologics Summit 2017

Neoantigen Summit 2017

ICI Summit Europe 2017

2nd Annual Cancer Immunotherapy Summit

6th International GMP, GCP & Quality Control Summit

Inhalation and Respiratory Drug Products Summit

NHS seal of approval for gestational diabetes app

Sanofi showcases eczema data ahead of EU decision

COPD triple approved, can GSK maximise its revenues?

Teva sells women’s health division to tackle $35bn debts

EU regulators reject Santhera’s Raxone for DMD

What is ‘affordable’? The reality of the PPRS

UK biotech round-up: Autolus joins CAR-T race, Horizon’s new CRISPR tech, Allergy Therapeutics’ grass gambit

Get real: virtual reality for healthcare comes of age

Unstable and unpredictable? The reality of the PPRS

Clinical trial summaries for lay people – unpicking the guidance

Search

Advanced Search

Trending

blood cancer